Somewhat Positive Media Coverage Somewhat Unlikely to Impact Ardelyx (ARDX) Share Price
Media headlines about Ardelyx (NASDAQ:ARDX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ardelyx earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.2801315018142 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Ardelyx (ARDX) opened at $5.90 on Tuesday. Ardelyx has a 1 year low of $4.05 and a 1 year high of $15.40.
Ardelyx (NASDAQ:ARDX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.10. During the same quarter in the previous year, the company earned ($0.65) earnings per share. research analysts predict that Ardelyx will post -2.01 earnings per share for the current fiscal year.
In other news, COO Reginald Seeto sold 10,008 shares of the company’s stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $5.20, for a total value of $52,041.60. The transaction was disclosed in a filing with the SEC, which is available through this link. 15.47% of the stock is owned by corporate insiders.
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.